Madrigal

1 known investors

Madrigal is a biopharmaceutical company developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious progressive liver disease. Its research led to the first FDA-approved treatment for MASH, aimed at halting or reversing liver fibrosis before cirrhosis develops.